TrialReader


Characteristics and Clinical Implications of a Clinical Decision Support System

NCT03295097 — Not applicable, Completed, 100 participants, Hospice of Henderson County, Inc.

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

A Prospective Multicenter Cohort Study to Evaluate The Characteristics and Clinical Implications of a Clinical Decision Support System and of Pharmacogenomic Information Relevant to Polypharmacy Actions in Patients With Advanced Illness Who Are Receiving Multiple Drugs for Pain and Other Disorders

RegistryNCT03295097
StatusCompleted
PhaseNot applicable
Study typeInterventional; na, single group, masking: none, supportive care
Enrollment100 (Actual)
SponsorHospice of Henderson County, Inc. (Other); collaborators: Tabula Rasa HealthCare
ConditionsChronic Illness, Opioid Use, Palliative Care
InterventionsClinical Decision Support System (Other)
Datesstart 2018-03-08, primary completion 2020-01-21, completion 2020-01-21, first posted 2017-09-27, last updated 2021-02-17
Locations2 sites in United States

Related Papers Related Patents Related Grants Related Experts
AI Assistant Save
All trials for Chronic Illness All trials for Opioid Use All trials of Clinical Decision Support System

-Summary

The investigators propose to study the feasibility, acceptability, usability and outcomes of a new clinical decision support system for clinicians of opioid therapy in the context of specialist palliative care for serious chronic illness. The system provides clinicians with patient-specific genetic information on opioid responsiveness and multi-drug interactions. This clinical decision support system should improve the clinician's ability to identify the optimal pain medication and dosage, and reduce risks associated with multi-drug treatment. Investigators will conduct clinician survey's to collection information about the clinical decision support system. Investigators will also conduct patient related questionnaires to determine any benefits or improvements in quality of life and symptom management from the clinical decision support system.

Expand all sections  ·  Collapse all

+Arms and interventions

ArmTypeInterventionsDescription
Clinical Decision Support SystemOtherOther: Clinical Decision Support SystemThe Clinical Decision Support System is composed of pharmacogenomic results and a pharmacist evaluated drug to drug interaction review. This system provides clinicians with patient-specific genetic information on opioid responsiveness and multi-drug interactions.
  • Clinical Decision Support System (Other): The system provides clinicians with patient-specific genetic information on opioid responsiveness and multi-drug interactions. This clinical decision support system should improve the clinician's ability to identify the optimal pain medication and dosage, and reduce risks associated with multi-drug treatment.

+Outcome measures

Primary outcomes

  • Clinician Feasibility [through study completion, an average of 24 months]: Clinical questionnaire to determine feasibility of the system
  • Clinician Usability [through study completion, an average of 24 months]: Clinical questionnaire to determine usability of the system

Secondary outcomes

  • Patient Quality of Life [through study completion,an average of 24 months]: Functional Assessment of Chronic Illness - Palliative (FACIT-PAL)
  • Patient Pain [through study completion, an average of 24 months]: Numerical Rating Scale to assess pain

+Eligibility

Sex: All, ages: 18 Years to any

Inclusion Criteria:

Clinicians will be eligible if:

1. Physicians or nurse practitioners who are practicing hospice and palliative care
2. Responsible for making and implementing decisions about opioid therapy for pain

Patients will be identified by their treating clinicians. Patients will be eligible if:

1. > 18 years of age
2. Palliative Performance Score ≥ 30%
3. Reside in the community or at a nursing home
4. Have >1 serious chronic illness
5. Have an assessed life-expectancy of at least 4 weeks
6. Have a history of pain and have been taking prescribed opioid medication with a regimen that provides a minimum dose of 20 mg morphine or equivalent per day in scheduled doses for at least one week prior to recruitment
7. Is expected to continue opioid therapy for the duration of study participation
8. Is taking > 4 non-opioid medications, each in a regimen providing continuous treatment of pain or another disorder
9. Is expected to continue drug therapy for the duration of study participation
10. Able to read, understand, and provide Informed Consent to participate

Exclusion Criteria:

There are no exclusion criteria for clinicians.

Patients will be excluded if:

1. Pregnant women or women trying to become pregnant or nursing. Women of childbearing potential must use an acceptable method of birth control for the duration of the study. (acceptable forms are oral birth control pills, condoms in combination with spermicide foam, IUD, transdermal patches, birth control implants, vaginal ring)
2. Palliative Performance Score <30%
3. Have taken an investigational product in the last 30 days
4. Current use of illicit substances
5. Immediate family members of site staff, or site staff may not be enrolled in the study without first obtaining IRB authorization
6. Any other medical or physical abnormality, disease, or disorder that would prohibit the patient from completing study procedures in the judgement of the investigator

+Locations (2)

FacilityCityCountryStatus
MJHS Hospice and Palliative CareNew York, New YorkUnited States
Hospice of Henderson County, Inc. d/b/a Four Seasons Compassion for LifeFlat Rock, North CarolinaUnited States

My Notes